Assessment of Hearing Impairment in Parkinson's Disease: Implications for Differential Diagnosis and Disease Progression

Mauro, Roberta Di; Lazzaro, Giulia Di; Schirinzi, Tommaso; Martino, Federica; Mercuri, Nicola Biagio; Fuccillo, Emanuela; Pisani, Antonio; Girolamo, Stefano Di

doi:10.4172/2161-0460.1000396

Cited by 7 publications

(9 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Generally, if CAS fails to reduce the OAE response amplitudes by 1 dB or more, ES is described as abnormal (35). In PD, abnormal ES of TEOAEs has been reported by Di Mauro et al (18). In this study, "increased TEOAE response amplitudes during CAS" were described in patients with PD.…”

Section: Otoacoustic Emissionssupporting

confidence: 60%

“…Indeed, a high-frequency age-related hearing impairment has been shown in studies that used pure-tone audiometry to evaluate the hearing sensitivity of patients with PD and age-matched control participants (HCs). On the one hand, multiple studies have demonstrated the same sloping audiometric pattern in patients with PD compared to HCs, consistent with the presence of an age-related hearing loss (17)(18)(19)(20). These studies did not find significant differences between patients with PD and HCs regarding pure-tone hearing thresholds.…”

Section: Audiological Measurements Peripheral Auditory Testsmentioning

confidence: 53%

“…Additionally, for research purposes, the response amplitudes of OAEs can be used for group comparisons. Regarding TEOAEs, two studies reported lower response amplitudes in medicated patients with PD compared to HCs (18,23). In contrast, De Keyser et al (17) found no significant differences regarding TEOAE response amplitudes between medicated patients with PD and age-matched HCs.…”

Section: Otoacoustic Emissionsmentioning

confidence: 97%

See 2 more Smart Citations

Future Perspectives on the Relevance of Auditory Markers in Prodromal Parkinson's Disease

et al. 2020

View full text Add to dashboard Cite

Research on auditory processing in Parkinson's disease (PD) has recently made substantial progress. At present, evidence has been found for altered auditory processing in the clinical stage of PD. The auditory alterations in PD have been demonstrated with low-cost and non-invasive assessments that are already used in routine clinical practice. Since auditory alterations have been reported early in disease progression, it would be highly relevant to investigate whether auditory markers could be provided in the prodromal stage of PD. In addition, auditory alterations in early stage PD might be modulated by dopaminergic medication. Therefore, the aim of this review is (1) to summarize the literature on auditory processing in PD with a specific focus on the early disease stages, (2) to give future perspectives on which audiological and electrophysiological measurements could be useful in the prodromal stage of PD and (3) to assess the effect of dopaminergic medication on potential auditory markers in the prodromal stage of PD.

show abstract

Section: Otoacoustic Emissionssupporting

confidence: 60%

Section: Audiological Measurements Peripheral Auditory Testsmentioning

confidence: 53%

Section: Otoacoustic Emissionsmentioning

confidence: 97%

See 1 more Smart Citation

Future Perspectives on the Relevance of Auditory Markers in Prodromal Parkinson's Disease

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A gold standard in the audiological examination and repeatedly studied in PD is pure-tone audiometry, a subjective measure of hearing sensitivity (Musiek et al, 2017). On the one hand, a number of studies did not find significant differences between patients with PD and age-matched healthy controls (HCs) regarding auditory thresholds (Al Jaja et al, 2020;De Keyser et al, 2019;Di Mauro et al, 2017;Lopes et al, 2018;Richardson & Sussman, 2019). On the other hand, studies have reported significantly higher auditory thresholds or a higher prevalence of hearing impairment in patients with PD compared to age-matched HCs, primarily in the high-frequency range (Al Zarea et al, 2016;Folmer et al, 2017;Hussein & Koura, 2019;Pisani et al, 2015;Scarpa et al, 2020;Shalash et al, 2017;Shetty et al, 2019;Vitale et al, 2016Vitale et al, , 2012Yýlmaz et al, 2009).…”

mentioning

confidence: 99%

“…This inhibitory effect causes a reduction of the OAE signal amplitude termed efferent suppression (ES). In patients with PD evaluated with dopaminergic medication, increased TEOAE signal amplitudes during contralateral acoustic stimulation (CAS) have been observed, suggesting reduced ES and a dysfunction of the MOC system (Di Mauro et al, 2017). In contrast, Lopes et al (2019) found generally normal ES of DPOAEs in patients with PD compared to HCs.…”

mentioning

confidence: 99%

The Effect of Parkinson's Disease on Otoacoustic Emissions and Efferent Suppression of Transient Evoked Otoacoustic Emissions

Groote

Bockstael

Botteldooren

et al. 2021

J Speech Lang Hear Res

View full text Add to dashboard Cite

Purpose Several studies have demonstrated increased auditory thresholds in patients with Parkinson's disease (PD) based on subjective tonal audiometry. However, the pathophysiological mechanisms underlying auditory dysfunction in PD remain elusive. The primary aim of this study was to investigate cochlear and olivocochlear function in PD using objective measurements and to assess the effect of dopaminergic medication on auditory function. Method Eighteen patients with PD and 18 gender- and age-matched healthy controls (HCs) were included. Patients with PD participated in medication on and off conditions. Linear mixed models were used to determine the effect of PD on tonal audiometry, transient evoked and distortion product otoacoustic emissions (OAEs), and efferent suppression (ES). Results Tonal audiometry revealed normal auditory thresholds in patients with PD for their age across all frequencies. OAE signal amplitudes demonstrated a significant interaction effect between group (PD vs. HC) and frequency, indicating decreased OAEs at low frequencies and increased OAEs at high frequencies in patients with PD. No significant differences were found between patients with PD and HCs regarding ES. In addition, no significant effect of medication status was found on auditory measurements in patients with PD. Conclusions Altered OAEs support the hypothesis of cochlear alterations in PD. No evidence was found for the involvement of the medial olivocochlear system. Altogether, OAEs may provide an objective early indicator of auditory alterations in PD and should complement subjective tonal audiometry when assessing and monitoring auditory function in PD.

show abstract

Central auditory processing in parkinsonian disorders: A systematic review

Groote

Keyser

Bockstael

et al. 2020

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

Assessment of Hearing Impairment in Parkinson's Disease: Implications for Differential Diagnosis and Disease Progression

Cited by 7 publications

References 19 publications

Future Perspectives on the Relevance of Auditory Markers in Prodromal Parkinson's Disease

Future Perspectives on the Relevance of Auditory Markers in Prodromal Parkinson's Disease

The Effect of Parkinson's Disease on Otoacoustic Emissions and Efferent Suppression of Transient Evoked Otoacoustic Emissions

Central auditory processing in parkinsonian disorders: A systematic review

Contact Info

Product

Resources

About